Remifentanil Requirement for Acceptable Intubating Condition

NCT ID: NCT02655380

Last Updated: 2019-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-19

Study Completion Date

2018-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ketamine and opioid are known to improve the intubating condition, respectively. Combination of ketamine and opioid potentiate analgesic effect and give hemodynamic stability in complementary manner. Therefore, the combination use of ketamine and remifentanil could be useful for acceptable intubating condition in the general anesthesia without the use of neuromuscular blocking agent. Generally, induction dose of ketamine ranges between 1 and 2 mg. There was no report about the optimal dose of remifentanil with 1 or 2 mg ketamine induction dose for intubation without neuromuscular blocking agent. The investigators focus on remifentanil dose using Dixon's up and down method.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intubating Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ketamine 1

Anesthesia induction with ketamine 1 mg followed by remifentanil.

Group Type EXPERIMENTAL

Ketamine 1

Intervention Type DRUG

Anesthesia induction is performed with 1 mg ketamine.

Remifentanil

Intervention Type DRUG

After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.

ketamine 2

Anesthesia induction with ketamine 2 mg followed by remifentanil.

Group Type EXPERIMENTAL

Ketamine 2

Intervention Type DRUG

Anesthesia induction is performed with 2 mg ketamine.

Remifentanil

Intervention Type DRUG

After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketamine 1

Anesthesia induction is performed with 1 mg ketamine.

Intervention Type DRUG

Ketamine 2

Anesthesia induction is performed with 2 mg ketamine.

Intervention Type DRUG

Remifentanil

After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA I-II
* Undergoing general anesthesia with endotracheal tube

Exclusion Criteria

* Anticipated difficult airway
* Patient with upper respiratory infection within 14 days
* Asthma
Minimum Eligible Age

3 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ajou University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

yun jeong chae

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

yun jeong chae, Ph.D

Role: STUDY_DIRECTOR

Ajou University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ajou universitiy school of medicine

Suwon, Gyeong-gi Do, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MED-DRU-15-354

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety of Remifentanil Infusion
NCT01303627 COMPLETED PHASE4
Dose of Remimazolam in Children for Intubation
NCT06170918 NOT_YET_RECRUITING NA
Ketamine and Propofol for Upper Endoscopy
NCT02295553 COMPLETED PHASE4